Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as maplirpacept (PF-07901801), PF-07901801, TTI-622
Maplirpacept · 2 trials · 3 indications
Part A only. To characterize the dose limiting toxicities (DLTs) of Maplirpacept.
Maximum Observed Plasma Concentration
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 1 week.
Number of participants with DLTs
| Arm | Type | Description |
|---|---|---|
| Maplirpacept (PF-07901801) | EXPERIMENTAL | single arm study |
| Name | Type | Description |
|---|---|---|
| Maplirpacept | DRUG | Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles. |
| maplirpacept (PF-07901801) | DRUG | maplirpacept (PF-07901801) |
Key Inclusion Criteria: * Histologically confirmed relapsed/refractory non-Hodgkin lymphoma without other effective therapeutic option. Or relapsed/refractory multiple myeloma exposed to therapies including PI, IMiD and anti-CD38 antibody. * With measurable disease * Eastern Cooperative Oncology Gr...
Top 20 of 70 competitors
Maplirpacept is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for oncology. It is being studied in hematologic cancers, specifically lymphoma, non-Hodgkin lymphoma, and multiple myeloma. It remains in clinical development and is not an approved therapy.
Maplirpacept is being studied for the treatment of hematologic malignancies, including non-Hodgkin lymphoma, lymphoma, and multiple myeloma. Research has been conducted in patients with advanced disease in China and Japan. It is investigational and has not been approved for any use.
Maplirpacept is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical studies evaluating the drug in patients with hematologic malignancies, including non-Hodgkin lymphoma and multiple myeloma.
Maplirpacept is in Phase 1 clinical development. Both of its recorded Phase 1 studies have been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA or any other regulatory authority.
Maplirpacept has been evaluated in two completed Phase 1 trials. NCT05896774 studied it in people with advanced non-Hodgkin lymphoma or multiple myeloma in China, enrolling 10 participants. NCT05567887 studied it in Japanese patients with hematologic malignancies, including lymphoma and multiple myeloma, enrolling 7 participants.
Yes. Maplirpacept is also known as PF-07901801. The two names refer to the same investigational small molecule developed by Pfizer, Inc. for hematologic malignancies. Searches for either name point to the same drug candidate and the same clinical development program.